Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma
|
|
- Winfred Ellis
- 8 years ago
- Views:
Transcription
1 Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma April 2008 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor of Surgery and Medicine David Geffen School of Medicine at UCLA
2 Case #1 22 yo F biology student 2.5 cm right thyroid nodule Euthyroid FNA: Sheets of follicular cells forming papillary structures, abundant nuclear grooves and intranuclear inclusions Further workup necessary? What is the most appropriate operation?
3 Surgeon-performed ultrasound
4
5
6 New plan? Total thyroidectomy Central (bilateral level 6) lymph node dissection Right modified radical neck dissection
7
8
9 Learning objectives Focus on papillary thyroid carcinoma Extent of initial surgery for PTC Is there a role for initial prophylactic lymph node dissection? Importance of ultrasound in initial staging Limitations of radioiodine therapy Impact of initial surgery on outcome and subsequent surveillance Surgeon s role in management of PTC recurrences
10 Thyroid cancer incidence is driven by PTC Davies L, Increasing incidence of thyroid cancer in the United States, , JAMA 2006.
11 Survival and Recurrence in PTC Bilimoria K, Extent of surgery affects survival for papillary thyroid cancer, Ann Surg 2007
12 Timing of Recurrences in PTC Mazzaferri E, Current approaches to primary therapy for papillary and follicular thyroid cancer, J Clin Endo Metab 2001
13 Prevalence of lymph node mets in PTC Ito Y, Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe, World J Surg, 2006
14 Prevalence of lymph node mets in PTC 30% 4% 45% Gimm O, Pattern of lymph node metastases in papillary thyroid carcinoma, Br J Surg 1998
15 Up to 39% of re-operations for thyroid cancer are a direct result of incomplete initial surgery Kouvaraki, Preventable reoperations for persistent and recurrent papillary thyroid carcinoma, Surgery 2004
16 What we know thus far PTC is increasingly common Survival remains excellent PTC <1 cm is not associated with cause-specific death Recurrences are common (30%) Most recurrences occur within 10 yrs of initial dx These are generally locoregional lymph node mets Recurrences may actually represent persistent disease Microscopic lymph node metastases of PTC are the rule Only a small fraction (1/4-1/3) of these go on to become clinically significant Most micrometastases remain quiescent!
17 What is the impact of PTC nodal mets? Conventional wisdom: No clinical impact (survival) Swedish study examining 5123 cases of DTC Cady B, Papillary carcinoma of the thyroid gland: Treatment based on risk group definition; Surg Oncol Clin N Am, 1998 Lundgren C, Clinically significant prognostic factors in differentiated thyroid carcinoma, Cancer 2005
18 What is the impact of PTC nodal mets? We found a 4-fold risk of recurrence and a 2.5-fold risk of cancer-specific death in patients with regional lymph node metastases. Loh K, Pathological tumor-nodemetastasis staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients, J Clin Endo Metab 1997
19 Surgeon s role in optimizing PTC care Management over the life span Prevent recurrences: survival impact, cost, risk of reoperation, emotional toll Make a personal investment in long term outcome Partner with the endocrinologist, esp. in high risk patients
20 Surgeon s role in optimizing PTC care For PTC >1 cm Total thyroidectomy: multifocality, give RAI, follow Tg Clear all palpable adenopathy at initial surgery Clear all sonographically detectable adenopathy at initial surgery Surgeon s responsibility to obtain high-quality pre-op US node survey for all FNA+ PTC and have a working knowledge of the lay of the land Prophylactic initial lymph node dissection?? Concept of compartment-oriented lymph node dissection
21
22 2006 ATA guidelines R27. Routine central-compartment (level VI) neck dissection should be considered for patients with papillary thyroid carcinoma and suspected Hürthle carcinoma. Near-total or total thyroidectomy without central node dissection may be appropriate for follicular cancer, and when followed by radioactive iodine therapy, may provide an alternative approach for papillary and Hürthle cell cancers Recommendation B The American Thyroid Association Guidelines Taskforce, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid 2006
23 Support for initial CND in PTC Goteborg study: 195 PTC patients studied prospectively Mean f/u 13 yrs Routine, meticulous bilateral central neck clearance RAI used sparingly Much lower CSM compared to controls Tissell L, Improved survival of patients with papillary thyroid cancer after surgical microdissection, World J Surg 1996 REVIEWED IN: White M, Central lymph node dissection in differentiated thyroid cancer, World J Surg 2007
24 Hannnover study: 342 pts, mean f/u 11.8 yrs Central compartment microdissection reduces CSM and recurrence Scheumann G, Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer, World J Surg 1994
25 Sydney study: 447 pts with PTC >1 cm and clinically negative nodes 56 underwent ipsilateral CND (2002 and beyond) Mean post-op, post-rai serum Tg lower in CND group Post-op, post-rai serum Tg more likely to be undetectable in CND group Sywak M, Routine ipsilateral level 6 lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer, Surgery 2006
26 CND: Technique
27
28
29 CND: Technique and complications Territory bounded by hyoid and thoracic inlet, both jugular veins Majority of yield is in triangular space bounded by midline, RLN, innominate vessels Routine auto-transplantation of inferior parathyroid Ipsilateral CND is generally sufficient no additional benefit to bilateral in terms of post-op Tg Permanent hypoparathyroidism % (3.1%) Permanent RLN paresis 0-4.2% (0.5%) Temporary RLN dysfunction may be higher No difference in long-term complication rate when performed by expert/high-volume surgeons
30 Radio-iodine: Myth and reality Conventional wisdom: Mops up residual disease after surgery Truth: Ineffective in treatment of macroscopic (incl. sonographically detectable) remnants and nodal disease Post-op RAI is given only for ablation of residual normal thyroid tissue (set Tg to zero) Even this is likely unnecessary after true TTx RAI is no substitute for excellent surgery Hay I, Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic s experience of treated 2,512 consecutive patients during 1940 through 2000, Trans Am Clin Climatol Assoc, 2002
31 Radioiodine and lymph node mets of PTC Primary tumors have reduced ability to take up RAI compared to normal thyroid 25% of WDTC are initially resistant to RAI Many nodal mets of PTC do not express NIS RAI has no effect on nodal mets >1 cm in diameter Likely has no effect on nodal mets of any size Clark O, Textbook of endocrine surgery, Elsevier Saunders 2005
32 Case: Radioiodine misuse 22F Dx 2.0 cm right PTC Total thyroidectomy in 2004 Post-op RAI 50 mci 2005 surveillance scan shows uptake in low central neck Treatment dose given, 150 mci RAI 2006 surveillance scan shows uptake in low central neck Treatment dose given, 200 mci RAI Tg 10.3 ng/ml after thyroxine withdrawal Next step?
33
34 Case: Radioiodine misuse FNA right level 3 lymph node + metastatic PTC Undergoes right modified radical neck dissection (levels 2, 3, 4) and right central neck dissection (level 6) Path: Right levels 2, 3, 4 1/11 lymph nodes positive Right level 6 1/1 lymph node positive No further RAI treatment Post-op US negative Post-op Tg undetectable No effect of cumulative dose 400 mci RAI on two subcentimeter lymph nodes!
35 Surgery vs Radioiodine Most PTC patients are low risk (MACIS score <6) For patients undergoing complete initial surgical clearance, RAI confers no additional benefit For patients who do not have complete initial surgical clearance, no amount of post-op RAI will improve the situation these patients need further surgery RAI benefits a small subset of high-risk PTC patients Works reasonably well for pulmonary metastases No impact on lymph node disease
36 Hay I, Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic s experience of treated 2,512 consecutive patients during 1940 through 2000, Trans Am Clin Climatol Assoc, 2002
37 Case: Piecework 34F Dx 2.5 cm right PTC in 1998 Op #1: Open bx right neck lymph node Op #2: Total thyroidectomy, lymph node sampling (+) Op #3: Take back for bleeding. Disease recurs. Permanent hypoparathyroidism Op #4: Right neck dissection. Disease recurs. Op #5: Re-do right neck dissection. Disease recurs : Tg elevated (144.6 ng/ml stimulated), multiple CTs, PET scans, MRIs all inconclusive Tg was never satisfactorily low May 2006 pt seeks care at UCLA
38
39
40 Case: Piecework Op #6: Re-do right level 2 clearance Op #7: Re-do right level 6 clearance Path: 3 of 9 nodes positive in level 2, and 3 of 4 nodes positive in level 6 Post-op Tg 2.0 ng/ml 7 operations over 10 years Countless labs, scans, procedures Acute on chronic disability Cost RE lost productivity, health care $$? QOL? Importance of compartment-oriented surgery
41 Case: Missing ultrasound 71M with 1.5 cm right thyroid mass FNA: Follicular neoplasm Plan right thyroid lobectomy Pt in OR under anesthetic
42
43
44
45
46
47
48 Ultrasound Essential for all surgeons interested in treating thyroid cancer Competent FLUENT Certification courses available through ACS: basic, head & neck, instructors course Make it a part of your daily practice: clinic & OR Many available platforms: Sonosite, GE, Terason Probes: 9-14 MHz linear array
49 Summary points Ultrasound is essential: EVERY cancer case Clear the neck of disease Do it right the first time around When you enter a nodal compartment, commit to clearing it completely No role for node picking Consider routine initial prophylactic ipsilateral central (level 6) lymph node dissection for FNA positive PTC >1 cm in diameter Have appropriately low expectations for what RAI can do Be vigilant for recurrences: surveillance US and Tg
Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationThyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD
Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence Cord Sturgeon, MD Associate Professor of Surgery Northwestern University Feinberg School of Medicine Director of Endocrine Surgery Chicago,
More informationRecurrent & Persistent Papillary Thyroid Cancer Central Nodal Dissection vs. Node-Picking Patterns of Nodal Metastases Recurrent Laryngeal Nerve,
Recurrent & Persistent Papillary Thyroid Cancer Central Nodal Dissection vs. Node-Picking Patterns of Nodal Metastases Recurrent Laryngeal Nerve, Larynx, Trachea, & Esophageal Management Robert C. Wang,
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationThyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules)
Thyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules) Jeffrey S. Freeman, D.O., F.A.C.O.I. Chairman, Division of Endocrinology and Metabolism Philadelphia College
More informationAdvances in Differentiated Thyroid Cancer
Advances in Differentiated Thyroid Cancer Steven A. De Jong, M.D., FACS, FACE Professor and Vice Chair Clinical Affairs Department of Surgery Loyola University Medical Center Thyroid Cancer classification
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationPapillary thyroid cancer accounts for approximately 90% Lymph Node Dissection in Papillary Thyroid Carcinoma
Lymph Node Dissection in Papillary Thyroid Carcinoma Tracy-Ann S. Moo, MD, and Thomas J. Fahey III, MD The management of papillary thyroid carcinoma continues to evolve. Although the debate over the extent
More informationLocoregional recurrence or persistence of papillary carcinoma: radioiodine treatment
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Michele Klain, Marco Salvatore Department of Functional and Biomorphological Science University of Naples "Federico
More informationFollowup of Patients with Papillary Thyroid Cancer: In Search of the Optimal Algorithm
Followup of Patients with Papillary Thyroid Cancer: In Search of the Optimal Algorithm Elizabeth A Mittendorf, MD, Xuemei Wang, MS, Nancy D Perrier, MD, Ashleigh M Francis, BSPH, Beth S Edeiken, MD, Suzanne
More informationPreventable reoperations for persistent and recurrent papillary thyroid carcinoma
Preventable reoperations for persistent and recurrent papillary thyroid carcinoma Maria A. Kouvaraki, MD, PhD, Jeffrey E. Lee, MD, Suzanne E. Shapiro, MS, Steven I. Sherman, MD, and Douglas B. Evans, MD,
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationManagement of Differentiated Thyroid Carcinoma American Thyroid Association Guidelines and Data from Kaohsiung Chang Gung Memorial Hospital
Review Management of Differentiated Thyroid Carcinoma American Thyroid Association Guidelines and Data from Kaohsiung Chang Gung Memorial Hospital Pei-Wen Wang Abstract Background. Most thyroid cancers
More informationThe Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.
Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD
More informationI Radiotherapy of Pediatric Thyroid Cancer
131 I Radiotherapy of Pediatric Thyroid Cancer Steven Waguespack, MD Associate Professor Dept of Endocrine Neoplasia and Hormonal Disorders Department of Pediatrics Patient Care University of Texas M.D.
More informationManagement of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed
Management of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed Medical Grand Rounds December 10,2015 Christine Signore, MD ECNU Learning Objectives Discuss the epidemiology
More informationThyroid Cancer Diagnosis and Management. Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010
Thyroid Cancer Diagnosis and Management Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010 DISCLOSURE NOTHING TO DISCLOSE in regard to financial conflict
More informationThyroid Cancer A Multidisciplinary Approach
Thyroid Cancer A Multidisciplinary Approach Shuvendu Sen, MD, MS, FACP Associate Program Director, Internal Medicine Residency Program Director, Medical Education Raritan Bay Medical Center, Rutgers University
More informationThyroid and Adrenal Gland
Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationTreating Thyroid Cancer using I-131 Maximum Tolerable Dose Method
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Christopher Martel, M.Sc., CHP Lisa Thornhill,, NRRPT, RT(NM) Boston University Medical Center Thyroid Carcinoma New cases and deaths in
More informationIl percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare
Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Maria Chiara Zatelli Sezione di Endocrinologia Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università
More informationHemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma
1412 Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma XIAOLONG LI 1*, CUI ZHAO 1*, DANDAN HU 1, YANG YU 1, JIN GAO 2, WENCHUAN
More informationManagement Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
THYROID Volume 16, Number 2, 2006 American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Taskforce*
More informationWELL DIFFERENTIATED THYROID CANCER
Scandinavian Journal of Surgery 93: 261 271, 2004 WELL DIFFERENTIATED THYROID CANCER N. R. Caron, O. H. Clark Department of Surgery, University of California, San Francisco and UCSF Comprehensive Cancer
More informationAACE/AAES MEDICAL/SURGICAL GUIDELINES FOR CLINICAL PRACTICE: MANAGEMENT OF THYROID CARCINOMA
AACE/AAES MEDICAL/SURGICAL GUIDELINES FOR CLINICAL PRACTICE: MANAGEMENT OF THYROID CARCINOMA Thyroid Carcinoma Task Force Co-Chairpersons Rhoda H. Cobin, MD, FACE Hossein Gharib, MD, FACP, FACE Committee
More informationThyroid Cancer Treatment in 2010
Rising U.S. Incidence of Thyroid Cancer ATA Guidelines Paul W. Ladenson, M.D. Brussels May 28, 2010 Davies & Welch. JAMA. 2006;295:2164-21672167 Rising U.S. Incidence of Thyroid Cancer LR: 38 y.o. computer
More information0021-972X/97/$03.00/0 Vol. 82, No. 11 Journal of Clinical Endocrinology and Metabolism Copyright 1997 by The Endocrine Society
0021-972X/97/$03.00/0 Vol. 82, No. 11 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society Pathological Tumor-Node-Metastasis (ptnm) Staging for Papillary
More informationIntensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer
Thyroid Science 5(1):CLS1-8, 2010 www.thyroidscience.com Clinical and Laboratory Studies Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer 1 2 5 Aruna Turaka, MD, Tianyu Li, MS, Jian Q. Yu,
More informationSalute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine
Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Douglas Van Nostrand, MD, FACP, FACNM Director, Nuclear Medicine
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationReoperation for Recurrent/Persistent Well-Differentiated Thyroid Cancer
Reoperation for Recurrent/Persistent Well-Differentiated Thyroid Cancer Sara I. Pai, MD, PhD a,b, Ralph P. Tufano, MD a, * KEYWORDS Recurrent/persistent papillary thyroid cancer Well-differentiated thyroid
More informationPediatric Thyroid Cancer: Treatment Controversies; I-131 Radiotherapy
Pediatric Thyroid Cancer: Treatment Controversies; I-131 Radiotherapy Marguerite T. Parisi, M.D., M.S. Ed. Associate Professor, Departments of Radiology and Pediatrics University of Washington School of
More informationConflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F.
Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates Jeffrey F. Krane, MD PhD Associate Professor of Pathology Harvard Medical School Chief, Head and Neck Pathology Service Associate Director,
More informationInfluence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma
ORIGINAL ARTICLE Influence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma Jasna Mihailovic, MD, PhD,*Þ Ljubomir Stefanovic, MD, PhD,* and Ranka
More informationMolecular Diagnostics in Thyroid Cancer
Disclosure Nothing to disclose Jonathan George, MD, MPH Assistant Professor Head and Neck Oncologic & Endocrine Surgery Molecular Diagnostics in Thyroid Cancer Current Practices & Future Trends UCSF Medical
More informationA Practical Guide to Advances in Staging and Treatment of NSCLC
A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging
More informationMANAGEMENT OF WELL DIFFERENTIATED THYROID CARCINOMA
MANAGEMENT OF WELL DIFFERENTIATED THYROID CARCINOMA These guidelines are intended to optimize the day-to-day care of patients with welldifferentiated thyroid cancer of follicular origin. They are not a
More informationPapillary Thyroid Cancer with Chest Metastases Only Detected Using Radioactive Iodine
Original Article 663 Papillary Thyroid Cancer with Chest Metastases Only Detected Using Radioactive Iodine Sheng-Fong Kuo, MD; Szu-Tah Chen, MD, PhD; Pan-Fu Kao 1, MD; Yu-Chen Chang 1, MD; Shuo-Chi Chou,
More informationCurrent Treatment of Papillary Thyroid Microcarcinoma
Advances in Surgery 46 (2012) 191 203 ADVANCES IN SURGERY Current Treatment of Papillary Thyroid Microcarcinoma Xiao-Min Yu, MD, PhD a, Ricardo Lloyd, MD, PhD b, Herbert Chen, MD c, * a Department of Surgery,
More informationBRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
More informationRevised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
THYROID Volume 19, Number 11, 2009 ª Mary Ann Liebert, Inc. DOI: 10.1089=thy.2009.0110 ORIGINAL STUDIES, REVIEWS, AND SCHOLARLY DIALOG THYROID CANCER AND NODULES Revised American Thyroid Association Management
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationSonographic Findings in the Surgical Bed After Thyroidectomy
Article Sonographic Findings in the Surgical Bed After Thyroidectomy Comparison of Recurrent Tumors and Nonrecurrent Lesions Jung Hee Shin, MD, Boo-Kyung Han, MD, Eun Young Ko, MD, Seok Seon Kang, MD Objective.
More informationReview Article To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients
Hindawi Publishing Corporation Journal of Oncology Volume 2012, Article ID 707156, 11 pages doi:10.1155/2012/707156 Review Article To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More information<1 cm WDT-UMP, FT-UMP. Kakudo K et al, Pathol Int,2009, Endocr J, 2011 and Pathol Int, 2012
More information
Thyroid Cancer Finding It and Treating It Using Radioiodine
Thyroid Cancer Finding It and Treating It Using Radioiodine Your doctor has referred you to Nuclear Medicine to learn more about the extent of your thyroid cancer, and perhaps even for treatment of the
More informationManagement of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin
Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin E L Mazzaferri 1 and N Massoll 2 1 Adjunct Professor of Medicine, University of
More informationThyroid Carcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2014. NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2014 NCCN.org Continue Version 2.2014, 08/12/2014 National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN
More informationReleasing Nuclear Medicine Patients to the Public: Dose Calculations and Discharge Instructions
Educational Objectives Releasing Nuclear Medicine Patients to the Public: Dose Calculations and Discharge Instructions Robert E. Reiman, MD Radiation Safety Division Duke University Medical Center Durham,
More informationEuropean consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
European Journal of Endocrinology (2006) 154 787 803 ISSN 0804-4643 CONSENSUS STATEMENT European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
More informationThe epidemic of thyroid cancer and its evolving management: Is less more?
The epidemic of thyroid cancer and its evolving management: Is less more? Julie Ann Sosa, MD MA FACS Professor of Surgery and Medicine Chief, Section of Endocrine Surgery, and Leader, Endocrine Neoplasia
More informationPredictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI)
Predictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI) D.A. Pizzuto1, S. Annunziata1, C. Brunelli2, G. Perotti1,
More informationShould All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases
PAPERS OF THE 131ST ASA ANNUAL MEETING Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases Xiao-Min Yu, MD, PhD, Yin Wan, MS, Rebecca S. Sippel, MD, FACS,
More informationOutcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy*
THYROID Volume 16, Number 12, 2006 ª Mary Ann Liebert, Inc. Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy* Jacqueline Jonklaas, 1 Nicholas J. Sarlis, 2{ Danielle
More informationValidation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach
Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Kerry C. Councilman, MD Assistant Professor University of Colorado Denver Goals: BRAF Mutation
More informationAdjuvant Radioactive Iodine Use Among Differentiated Thyroid Cancer Patients in the Military Health System
MILITARY MEDICINE, 179, 9:1043, 2014 Adjuvant Radioactive Iodine Use Among Differentiated Thyroid Cancer Patients in the Military Health System Abegail A. Gill, MPH*; Lindsey Enewold, PhD*; Shelia H. Zahm,
More informationControlling recurrent papillary thyroid carcinoma in the neck by ultrasonographyguided
Eur Radiol (2008) 18: 835 842 DOI 10.1007/s00330-007-0809-5 HEAD AND NECK Byung Moon Kim Min Jung Kim Eun-Kyung Kim Sung Il Park Cheong Soo Park Woong Youn Chung Controlling recurrent papillary thyroid
More informationVC 2012 The American Laryngological, Rhinological and Otological Society, Inc. TRIOLOGICAL SOCIETY CANDIDATE THESIS
The Laryngoscope VC 2012 The American Laryngological, Rhinological and Otological Society, Inc. TRIOLOGICAL SOCIETY CANDIDATE THESIS Reoperative Central Compartment Dissection for Patients With Recurrent/Persistent
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationBRAF as a prognostic marker in papillary thyroid cancer
12 Congresso Nazionale AME Molecular markers in thyroid cancer: current role in clinical practice BRAF as a prognostic marker in papillary thyroid cancer Dott. ssa Cristina Romei Sezione di Endocrinologia
More informationThyroglobulin. versie 071120 J. Billen LAG-UZ-KULeuven 1
Thyroglobulin Large glycoprotein Two identical polypeptide chains 660 kda Prohormone in the intra-thyroid T4 and T3 synthesis Produced only by normal thyrocytes or well-differentiated thyroid cancer (DTC)
More informationGENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE
Genomics in Medicine Series GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE Electron Kebebew, MD, FACS Outline To assess the change in thyroid cancer epidemiology
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationWell-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival
Singapore Med J 2002 Vol 43(9) : 457-462 O r i g i n a l A r t i c l e Well-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival L H Y Lim, K C Soo, Y K Chong, F Gao, G S Hong,
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationThe incidence of thyroid cancer has increased exponentially over
FEATURE THYROID Papillary thyroid cancer: the most common endocrine malignancy JAMES C. LEE FRACS STANLEY B. SIDHU FRACS, PhD Papillary thyroid cancer has an excellent prognosis and over 90% of affected
More informationMEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID EFFECTIVE DATE: 11/19/15
MEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationATLAS OF HEAD AND NECK PATHOLOGY THYROID PAPILLARY CARCINOMA
Papillary carcinoma is the most common of thyroid malignancies and occurs in all age groups but particularly in women under 45 years of age. There is a high rate of cervical metastatic disease and yet
More informationThyroid Gland Disease. Zdeněk Fryšák 3rd Clinic of Internal Medicine Nephrology-Rheumatology-Endocrinology Faculty Hospital Olomouc
Thyroid Gland Disease Zdeněk Fryšák 3rd Clinic of Internal Medicine Nephrology-Rheumatology-Endocrinology Faculty Hospital Olomouc t 1/2 = 5-7d t 1/2 = < 24 hrs Normal Daily Thyroid Secretion Rate:
More informationOriginal Investigation
Research Original Investigation Lack of Association of BRAF Mutation With Negative Prognostic Indicators in Papillary Thyroid Carcinoma The University of California, San Francisco, Experience Christopher
More informationWhat s new in Endocrine Surgery?
What s new in Endocrine Surgery? THE COOL, THE CONTROVERSIAL AND THE CRAZY CORTNEY Y. LEE, M.D. ASSISTANT PROFESSOR OF SURGERY SECTION OF ENDOCRINE SURGERY Objectives Define endocrine surgery Review changes
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationThyroid Surgery at Massachusetts General Hospital Frequently Asked Questions
Thyroid Surgery at Massachusetts General Hospital Frequently Asked Questions Q: What is the thyroid gland? A: The thyroid is a butterfly-shaped gland located in the front of the neck. It is one of the
More informationClinicopathological features of recurrent papillary thyroid cancer
Zhu et al. Diagnostic Pathology (2015) 10:96 DOI 10.1186/s13000-015-0346-5 RESEARCH Open Access Clinicopathological features of recurrent papillary thyroid cancer Jian Zhu 1, Xinli Wang 2, Xiaoxuan Zhang
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More information13 Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer
13 Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer John C. Watkinson Introduction The majority of patients with differentiated thyroid cancer have papillary carcinoma and most are treated
More information2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
THYROID Volume 26, Number 1, 2016 ª American Thyroid Association ª Mary Ann Liebert, Inc. DOI: 10.1089/thy.2015.0020 SPECIAL ARTICLE 2015 American Thyroid Association Management Guidelines for Adult Patients
More informationThe 2015 American Thyroid Association Guidelines for Thyroid Nodules and Differentiated Cancer: An Author s Perspective
The 2015 American Thyroid Association Guidelines for Thyroid Nodules and Differentiated Cancer: An Author s Perspective AACE 2015 Hot Topics in Thyroid Practice May 13, 2015 Bryan R. Haugen, MD University
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationCorporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid
Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid
More informationImage. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.
Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationEvidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
More informationThe Relationship Between Lymphocytic Infiltration in the Thyroid Gland and Tumor Recurrence in Papillary Thyroid Carcinoma
Turkish Journal of Endocrinology and Metabolism, (1999) 3 : 113-117 ORIGINAL ARTICLE The Relationship Between Lymphocytic Infiltration in the Thyroid Gland and Tumor Recurrence in Papillary Thyroid Carcinoma
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationPrediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma
Clinical Endocrinology (2014) 81, 282 288 doi: 10.1111/cen.12417 ORIGINAL ARTICLE Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma Yinlong Yang*,, Chengze Chen,
More informationHow To Treat Lung Cancer At Cleveland Clinic
Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationOxford Centre for Head and Neck Oncology The Thyroid Gland and Thyroid Cancer Information for patients
Oxford University Hospitals NHS Trust Oxford Centre for Head and Neck Oncology The Thyroid Gland and Thyroid Cancer Information for patients What is the thyroid gland? The thyroid gland is an endocrine
More informationThe American Joint Committee on Cancer (AJCC)
THY-2012-0043-ver9-Randolph_3P.3d 10/13/12 6:42am Page 1 THYROID Volume 22, Number 11, 2012 ª Mary Ann Liebert, Inc. DOI: 10.1089/thy.2012.0043 THYROID CANCER AND NODULES The Prognostic Significance of
More information